The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nipocalimab as a potential treatment option for adults with systemic lupus erythematosus (SLE), which is an autoantibody-driven condition. This condition affects approximately 3-5 million individuals globally, including around 450,000 in the United States. This product is being developed by Johnson & Johnson. The Fast Track program is designed to accelerate the development and regulatory review of potential drugs to treat serious conditions with significant unmet medical needs.
SLE is a chronic autoimmune disease in which the immune system attacks healthy tissues. This causes inflammation as well as damage to the various organs, such as the nervous system, heart, brain, kidneys, skin, blood, joints, and lungs. This condition occurs 9 times more often in women than in men, typically between the ages of 15 and 44 years. Common symptoms include Joint pain, rashes (characteristic butterfly facial rash), severe fatigue, and swelling. Persistent inflammation and disease flares, as well as long-term steroid use, can lead to reduced quality of life and irreversible organ damage.
Nipocalimab is an investigational immunoselective therapy that lowers harmful IgG antibodies while preserving essential immune functions by blocking the neonatal Fc receptor (FcRn) in the placenta. It is being studied for autoimmune conditions across maternal-fetal disease, rheumatologic diseases, and rare autoantibody disorders, where FcRn blockade may reduce placental transfer of harmful maternal alloantibodies to the fetus.
After positive results from Phase 2b JASMINE clinical trial (NCT04882878), Jhonson & Johnson began enrolling patients in the GRADENIA (NCT07438496) clinical study for adults with moderate or severe SLE (n = 600, age = 18 to 75 years). This clinical trial was a multicenter, placebo-controlled, double-blind, randomized, and Phase 3 trial. Nipocalimab is the first FcRn blocker showing reduced SLE activity that met the primary and secondary outcomes, including potential steroid-sparing effects. The drug remains investigational and is not yet approved.
The U.S. FDA and European Medicines Agency (EMA) have granted multiple designations to nipocalimab, including Priority Review, Orphan Drugs, Breakthrough Therapy, and Fast Track. These cover conditions such as SLE, generalized myasthenia gravis (gMG), hemolytic disease of the fetus and newborn (HDFN), sjogren’s disease, chronic inflammatory demyelinating polyneuropathy (CIDP), fetal and neonatal alloimmune thrombocytopenia (FNAIT), and warm autoimmune hemolytic anemia (wAIHA), which reflects its potential to address a range of serious autoimmune and maternal-fetal disorders.
Dr. Leonard L. Dragone, MD, from the development team, announced that “nipocalimab has received its fifth U.S. FDA Fast Track designation, now for SLE. This designation highlights the requirement to accelerate the development of an immunoselective therapy that may address significant unmet needs for patients with this type of autoimmune disease. Development efforts with the FDA are ongoing to evaluate its potential as a treatment option for individuals with SLE.”
Richard Furie, MD, Chief of the Division of Rheumatology, Northwell Health, said that SLE is a complex disease with limited treatment options that significantly affect patients’ quality of life. He also noted that advances like this offer hope for more targeted therapies and improved clinical outcomes for people with this debilitating condition.
Reference: Johnson & Johnson. Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE). PR Newswire. Published March 03, 2026. Accessed March 13, 2026. https://www.prnewswire.com/news-releases/johnson–johnson-therapy-nipocalimab-granted-us-fda-fast-track-designation-in-systemic-lupus-erythematosus-sle-302701627.html
